trending Market Intelligence /marketintelligence/en/news-insights/trending/CYM8mNdCaURNGPQR3XrgDA2 content esgSubNav
In This List

Albireo Pharma seeks approval for chronic constipation drug in Japan

Blog

Debt Ceiling Debate: IR Teams Should Prepare for Potential Market Downturns

Blog

Insight Weekly: Loan-to-deposit ratio rises; inventory turnovers ebb; miners add female leaders

Blog

Insight Weekly: Sustainable bonds face hurdles; bad loans among landlords; AI investments up

Blog

Insight Weekly: Bank oversight steps up; auto insurers’ dismal year; VC investment slumps


Albireo Pharma seeks approval for chronic constipation drug in Japan

Albireo Pharma Inc. said EA Pharma Co. Ltd. filed a new drug application to the Japanese Pharmaceuticals and Medical Devices Agency for elobixibat, a chronic constipation drug.

EA Pharma holds the exclusive license for elobixibat as gastrointestinal disorder treatment in Japan and other select countries in Asia.

If approved, EA Pharma will co-market the drug in Japan with Mochida Pharmaceutical Co. Ltd.

Elobixibat is an orally available ileal bile acid transporter inhibitor that helps improve secretion and motility in the large bowel. In a phase 3 clinical trial, the drug met the primary endpoint, change in the number of weekly spontaneous bowel movements from baseline to the first treatment week compared with placebo, with high statistical significance.